title: CTX-M beta-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia.
abstract: Despite the recent global spread of CTX-M beta-lactamases in Escherichia coli isolates from community-acquired urinary tract infections (CA-UTIs), their dissemination has been little studied in developing countries. In a 2-year prospective study, we documented the prevalence of extended-spectrum beta-lactamases (ESBLs) in E. coli that were responsible for CA-UTIs in Phnom-Penh, Cambodia. Ninety-three E. coli strains were included. We observed a high prevalence of resistance to amoxicillin (88.2% of strains), cotrimoxazole (75.3%), ciprofloxacin (67.7%), gentamicin (42.5%), and third-generation cephalosporins (37.7%). A total of 34 strains carried ESBLs, all of which were CTX-M type. CTX-M carriage was associated with resistance to fluoroquinolones and aminoglycosides. U using repetitive extragenic palindromic-PCR, we identified 4 clusters containing 9, 8, 3, and 2 strains. The prevalence of CTX-M beta-lactamases has reached a critical level in Cambodia, which highlights the need for study of their spread in developing countries.
authors.affiliation: Institut Pasteur du Cambodge, Phnom Penh, Cambodia. etienne.ruppe@gmail.com
authors.forename: Etienne
authors.initials: E
authors.lastname: Ruppé
authors.forename: Sopheak
authors.initials: S
authors.lastname: Hem
authors.forename: Sovannarith
authors.initials: S
authors.lastname: Lath
authors.forename: Valérie
authors.initials: V
authors.lastname: Gautier
authors.forename: Frédéric
authors.initials: F
authors.lastname: Ariey
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Sarthou
authors.forename: Didier
authors.initials: D
authors.lastname: Monchy
authors.forename: Guillaume
authors.initials: G
authors.lastname: Arlet
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002160:Cambodia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000453:epidemiology* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D014552:Urinary Tract Infections / Q000453:epidemiology* / Q000382:microbiology; D055815:Young Adult; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D001618:beta-Lactamases